A novel series of dimethyl triazene incorporated thiazolyl pyrazolines have been designed on the basis of hybridization and also in support with combi‐targeting approach. The designed compounds were synthesized through facile synthetic methods, and the compounds were confirmed by 1H NMR, 13C NMR, MS, and elemental analysis. Further, compounds were screened for in vitro anticancer activity against human breast cancer (MCF‐7) and human colon cancer (HT‐29) cell lines by MTT assay. Among all the tested compounds, compound 9b showed highest activity against both the cell lines in comparison with reference drug, Cisplatin. In addition, the synthesized compounds were docked into VEGFR‐2 kinase (PDB code: 2XIR) to explore their binding interactions at the active site. The compounds showed essential key interactions as that of known VEGFR‐2 inhibitors, and hence, the synthesized compounds may be considered as molecular scaffolds for anticancer activity.
A novel series of imidazo[1,2-a]pyridine based 1H-1,2,3-triazole derivatives were designed, synthesized, and evaluated for their anticancer activity against two different human cancer cell lines. Most of the synthesized compounds displayed anticancer activity with IC 50 values from 2.35 to 120.46 μM. Furthermore, compounds 9b, 9c, 9d, 9f, and 9j showed potent inhibitory activity against cancer cell lines, with IC 50 values close to that of standard drug. It is important to note that compound 9d was more potent than the standard drug cisplatin with IC 50 values of 10.89 and 2.35 μM against Hela cell line and MCF-7 cell line, respectively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.